Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer

FİLİPOVİC, Nenad; DUBİNSKY, Pavol; ÖZYİĞİT, Gökhan; JEREMİC, Branislav

doi:10.5505/tjo.2019.2079

Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer

Branislav JEREMİC, (Department of Oncology, Bio IRC)

Gökhan ÖZYİĞİT, (Hacettepe Üniversitesi)

Pavol DUBİNSKY, (Department of Radiation Oncology, East Slovakia Institute of Oncology)

Nenad FİLİPOVİC (Department of Oncology, Bio IRC)

Türk Onkoloji Dergisi

1 0

Yıl: 2019 Cilt: 34 Sayı: 3 Sayfa Aralığı: 204 - 214 Metin Dili: İngilizce DOI: 10.5505/tjo.2019.2079 İndeks Tarihi: 05-05-2020

Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer

Öz:

The last three decades provided new insights into the discovery of the entity related to several strainsof human papillomavirus (HPV). The viral cause of HPV, primarily found in the oropharynx, was officially recognized by the World Health Organization in 2007. While epidemiologic studies around theworld showed an increased incidence of HPV-related heads and neck cancers (HNC), they also established a photo robot of a typical person suffering from HPV: younger white man, suffering from a nonkeratinized type of squamous cell carcinoma, rarely being seen as heavy smoker and/or drinker. Thepatient with specific sexual behavior pattern usually carried low T and high N burden, HPV16 beingdetected in the vast majority of HPV+ tumors, mostly in the oropharynx. It was also recognized thatHPV-related cancers seem to have a better prognosis than their HPV-unrelated counterparts. This observation served as an important starting point for clinical studies aiming first to identify different riskgroups and then to design various de-intensification treatment strategies which aimed to maintain highsuccess rate with e.g. lower radiotherapy and/or chemotherapy doses while decreasing side effects suchdeintensified treatment strategies should bring. This review summarizes the most important aspects ofHPV-related HNC.

Anahtar Kelime:

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin; 57(1):43-66.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5–29.
4. Kreimer, A, Clifford G, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-75.
5. World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans - Monograph 90. Lyon, France: International Agency for Research on Cancer; 2007.
6. Dahlstrom KR, Calzada G, Hanby JD, Garden AS, Glisson BS, Li G,et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer. 2013;119(1): 81-9.
7. Straetmans JM, Olthof N, Mooren JJ, de Jong J, Speel EJ, Kremer B. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope. 2009; 119(10):1951-7.
8. Keane FK, Chen YH, Neville BA, Tishler RB, Schoenfeld JD, Catalano PJ et al. Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer. 2015; 121(15): 2594-602.
9. Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American Joint Committee on Cancer/ Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 2015; 33 (8):836-45.
10.O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440-51
11.Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg. 1983;12(6):418-24.
12.de Villiers EM, Neumann C, Le JY, Weidauer H, zur Hausen H. Infection of the oral mucosa with defined types of human papillomaviruses. Med Microbiol Immunol. 1986; 174(6):287-94.
13.Niedobitek G, Pitteroff S, Herbst H, Shepherd P, Finn T, Anagnostopoulos I, et al. Detection of human papil-lomavirus type 16 DNA in carcinomas of the palatine tonsil. J Clin Pathol. 1990; 43(11):918-21.
14.Snijders PJ, Cromme FV, van den Brule AJ, Schrijnemakers HF, Snow GB, Meijer CJ, et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer. 1992; 51(6):845–50.
15.Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, et al. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res.1996; 2(4):755–62.
16.Steinberg BM, DiLorenzo TP. A possible role for human papillomaviruses in head and neck cancer.Cancer Metastasis Rev. 1996; 15(1):91-112.
17.Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer. 1997; 79(3):595-604.
18.McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck. 1998; 20(3):250-65.
19.Wilczynski SP, Lin BT, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol. 1998; 152(1):145–56.
20.Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control.Cancer Res. 1998; 58(1):5-13.
21. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92(9):709–20.
22.Ragin CC, Taioli E, Weissfeld JL, White JS, Rossie KM, Modugno F, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer. 2006; 95(10):1432-8.
23.D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356(19):1944-56.
24.Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018; 142(5):559-97
25.Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol. 2018; 36(31):3152-61
26 Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576–82.
27.Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015; 21(3):632–41.
28.Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene- expressing human papillomavirus. Oncogene. 2006; 25(17):2558–64.
29.Hayes DN, Van Waes C, Seiwert TY. Genetic Landscape of Human Papillomavirus- Associated Head and Neck Cancer and Comparison to Tobacco- Related Tumors. J Clin Oncol. 2015; 33(29):3227–34.
30.Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 28(27):4142–48.
31.Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015; 21(4):870–81.
32.Seiwert T, Burtness B, Weiss J, Eder JP,r, Yearley J, Murphy E, et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. J Clin Oncol. 2015; 33(suppl):abstr 6017.
33.Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014; 50(5): 380–6.
34.Junor E, Kerr G, Oniscu A, Campbell S, Kouzeli I, Gourley C, et al. Benefit of chemotherapy as part of treatment for HPV DNA-positive but P16-negative squamous cell carcinoma of the oropharynx. Br. J. Cancer 2012; 106(2):358–65.
35.Ernster JA, Sciotto CG, O’Brien MM, Finch JL, Robinson LJ, Willson T, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007; 117(12):2115-28.
36.Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006; 24(36):5630-6.
37.Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006; 24(5):736-47
38.Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26(4):612-9
39.Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007; 110(7):1429-35.
40.Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years.Cancer. 2005; 103(9):1843-9.
41.Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006; 119(11):2620-3.
42.Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J.Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009; 27(12):1992-8.
43.Hocking JS, Stein A, Conway EL, Regan D, Grulich A, Law M, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers.Br J Cancer. 2011; 104(5):886-91
44.Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol. 2008; 19(10):1681-90.
45.Abogunrin S, Di Tanna GL, Keeping S, Carroll S, Iheanacho I. Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis.BMC Cancer. 2014; 14:968.
46.Van Rensburg EJ, van Heerden WF, Venter EH, Raubenheimer EJ. Detection of human papillomavirus DNA with in situ hybridisation in oral squamous carcinoma in a rural black population. S Afr Med J. 1995; 85(9):894-6.
47.Van Rensburg EJ, Engelbrecht S, Van Heerden WF, Raubennheimer EJ, Schoub BD. Human papillomavirus DNA in oral squamous cell carcinomas from an African population sample. Anticancer Res. 1996; 16(2):969-73.
48.Boy S, Van Rensburg EJ, Engelbrecht S, Dreyer L, van Heerden M, van Heerden W.HPV detection in primary intra-oral squamous cell carcinomas--commensal, aetiological agent or contamination? J Oral Pathol Med. 2006; 35(2):86-90
49.Ibrahim SO, Bertelsen B, Kalvenes MB, Idris AM, Vasstrand EN, Nilsen R, et al. Expression of keratin 13, 14 and 19 in oral squamous cell carcinomas from Sudanese snuff dippers: lack of association with human papillomavirus infection.APMIS. 1998; 106(10):959-69.
50.Zhu C, Ling Y, Dong C, Zhou X, Wang F.The relationship between oral squamous cell carcinoma and human papillomavirus: a meta-analysis of a Chinese population (1994-2011). PLoS One. 2012; 7(5):e36294
51.Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010.JAMA. 2012; 307(7):693-703.
52.Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, et al.Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection.J Natl Cancer Inst. 1998; 90(21):1626-36.
53.Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, et al.Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004; 108(5):766-72.
54.D’Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009; 199(9):1263-9.
55.Widdice LE, Breland DJ, Jonte J, Farhat S, Ma Y, Leonard AC, et al.Human papillomavirus concordance in heterosexual couples. J Adolesc Health. 2010; 47(2):151-9.
56.Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan’gina O, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010; 39(1):166-81.
57.Dahlstrom KR, Li G, Tortolero-Luna G, Wei Q, Sturgis EM.Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites.Head Neck. 2011; 33(6):847-55.
58.Kreimer AR, Villa A, Nyitray AG, Abrahamsen M, Papenfuss M, Smith D, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev. 2011; 20(1):172-82.
59.Pickard RK, Xiao W, Broutian TR, He X, GillisonML. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis. 2012; 39(7):559-66.
60.Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, et al. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis. 2012; 39(11):860-7.
61.D’Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014; 32(23):2408-15.
62.Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, et al.Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis. 2004; 189(4):686-98
63.Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP, et al.Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol. 2008; 44(3):242-50.
64.Riethdorf S, Friedrich RE, Ostwald C, Barten M, Gogacz P, Gundlach KK, et al. p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: a long-term follow-up study. J Oral Pathol Med. 1997; 26(7):315-21.
65.Chiba I, Shindoh M, Yasuda M, Yamazaki Y, Amemiya A, Sato Y, et al.Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene. 1996; 12(8):1663-8.
66.Portugal LG, Goldenberg JD, Wenig BL, Ferrer KT, Nodzenski E, Sabnani JB, et al. Human papillomavirus expression and p53 gene mutations in squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1997; 123(11):1230-4.
67.Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer. 2000; 89(3):300-4.
68.Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007; 121(8):1813-20.
69.Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010; 2:15.
70.Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma.Cancer. 2001; 92(4):805-13.
71.Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.J Natl Cancer Inst. 2008; 100(4):261-9.
72.Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al.Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35
73.O’Sullivan B, Huang SH, Perez-Ordonez B, Massey C, Siu LL, Weinreb I, et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol. 2012; 103(1):49-56.
74.Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, et al. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. JClinOncol. 2016; 34(12):1300-8.
75.Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, et al. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer. 2016; 67:174-82.
76.O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013; 31(5):543-50.
77.Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, et al. Treatment de-escalation in HPVpositive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer. 2015; 136(7):1494-503.
78.Huang J, Zhang J, Shi C, Liu L, Wei Y. Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. BMC Cancer 2016; 16: 689.
79.Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A et al. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol 2016; 3(2): 220–6.
80.Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017; 35(5):490-7.
81.Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papil- lomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017; 18(6):803-11.
82.Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019; 393(10166):40-50.
83.Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78.
84.Riaz N, Sherman E, Koutcher L, Shapiro L, Katabi N, Zhang Z, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol 2016; 39(1): 27–31
85.Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD, et al. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck 2015; 37(3): 386–92.
86.Barney CL, Walston S, Zamora P, Healy EH, Nolan N, Diavolitsis VM, et al. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. Oral Oncol 2018; 79: 9–14.
87.Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 2015; 16(2): 221–32.
88.Magrini SM, Buglione M, Corvò R, Pirtoli L, Paiar F, Ponticelli P, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol 2016; 34(5): 427–35
89.Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.Lancet. 2019; 3 93(10166): 51-60.

APA	JEREMİC B, ÖZYİĞİT G, DUBİNSKY P, FİLİPOVİC N (2019). Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. , 204 - 214. 10.5505/tjo.2019.2079
Chicago	JEREMİC Branislav,ÖZYİĞİT Gökhan,DUBİNSKY Pavol,FİLİPOVİC Nenad Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. (2019): 204 - 214. 10.5505/tjo.2019.2079
MLA	JEREMİC Branislav,ÖZYİĞİT Gökhan,DUBİNSKY Pavol,FİLİPOVİC Nenad Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. , 2019, ss.204 - 214. 10.5505/tjo.2019.2079
AMA	JEREMİC B,ÖZYİĞİT G,DUBİNSKY P,FİLİPOVİC N Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. . 2019; 204 - 214. 10.5505/tjo.2019.2079
Vancouver	JEREMİC B,ÖZYİĞİT G,DUBİNSKY P,FİLİPOVİC N Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. . 2019; 204 - 214. 10.5505/tjo.2019.2079
IEEE	JEREMİC B,ÖZYİĞİT G,DUBİNSKY P,FİLİPOVİC N "Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer." , ss.204 - 214, 2019. 10.5505/tjo.2019.2079
ISNAD	JEREMİC, Branislav vd. "Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer". (2019), 204-214. https://doi.org/10.5505/tjo.2019.2079

APA	JEREMİC B, ÖZYİĞİT G, DUBİNSKY P, FİLİPOVİC N (2019). Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi, 34(3), 204 - 214. 10.5505/tjo.2019.2079
Chicago	JEREMİC Branislav,ÖZYİĞİT Gökhan,DUBİNSKY Pavol,FİLİPOVİC Nenad Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi 34, no.3 (2019): 204 - 214. 10.5505/tjo.2019.2079
MLA	JEREMİC Branislav,ÖZYİĞİT Gökhan,DUBİNSKY Pavol,FİLİPOVİC Nenad Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi, vol.34, no.3, 2019, ss.204 - 214. 10.5505/tjo.2019.2079
AMA	JEREMİC B,ÖZYİĞİT G,DUBİNSKY P,FİLİPOVİC N Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi. 2019; 34(3): 204 - 214. 10.5505/tjo.2019.2079
Vancouver	JEREMİC B,ÖZYİĞİT G,DUBİNSKY P,FİLİPOVİC N Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi. 2019; 34(3): 204 - 214. 10.5505/tjo.2019.2079
IEEE	JEREMİC B,ÖZYİĞİT G,DUBİNSKY P,FİLİPOVİC N "Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer." Türk Onkoloji Dergisi, 34, ss.204 - 214, 2019. 10.5505/tjo.2019.2079
ISNAD	JEREMİC, Branislav vd. "Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer". Türk Onkoloji Dergisi 34/3 (2019), 204-214. https://doi.org/10.5505/tjo.2019.2079